Ospina Aylen Vanessa, Brugés Ricardo, Triana Iván, Sánchez-Vanegas Guillermo, Barrero Angela, Mantilla William, Ramos Pedro, Bernal Laura, Aruachán Sandra, González Manuel, Lobatón José, Quiroga Alicia, Rivas Giovanna, González Guido, Lombana Milton, Munevar Isabel, Jiménez Paola, Avendaño Ana Cristina, Arias Mirian Caicedo, López Carolina, González Héctor, Pacheco Javier, Manneh Ray, Pinilla Paola, Russi Andrea, Ortiz Juan, Insuasty Jesús, Alcalá Carmen, Contreras Fernando, Bogoya Juliana
ICCAL Fundación Santa Fe de Bogotá. Asociación Colombiana de Hematología y Oncología - ACHO.
Instituto Nacional de Cancerología - Pontificia Universidad Javeriana.
J Cancer. 2023 Jul 31;14(13):2410-2416. doi: 10.7150/jca.79969. eCollection 2023.
During the pandemic, it has been recommended that vaccination against COVID-19 be a priority for patients with cancer; however, these patients were not included in the initial studies evaluating the available vaccines. To define the impact of vaccination against COVID-19 in preventing the risk of complications associated with the infection in a cohort of patients with cancer in Colombia. An analytical observational cohort study, based on national registry of patients with cancer and COVID 19 infection ACHOC-C19, was done. The data was collected from June 2021, until October 2021. Inclusion criteria were: Patients older than 18 years with cancer diagnosis and confirmed COVID-19 infection. Data from the unvaccinated and vaccinated cohorts were compared. Outcomes evaluated included all-cause mortality within 30 days of COVID-19 diagnosis, hospitalization, and need for mechanical ventilation. The estimation of the effect was made through the relative risk (RR), the absolute risk reduction (ARR) and the number needed to treat (NNT). Multivariate analysis was performed using generalized linear models. : 896 patients were included, of whom 470 were older than 60 years (52.4%) and 59% were women (n=530). 172 patients were recruited in the vaccinated cohort and 724 in the non-vaccinated cohort (ratio: 1 to 4.2). The cumulative incidence of clinical outcomes among the unvaccinated vs vaccinated patients were: for hospitalization 42% (95% CI: 38.7%-46.1%) vs 29%; (95% CI: 22.4%-36.5%); for invasive mechanical ventilation requirement 8.4% (n=61) vs 4.6% (n=8) and for mortality from all causes 17% (n=123) vs 4.65% (n=8). In our population, unvaccinated patients with cancer have an increased risk of complications for COVID -19 infection, as hospitalization, mechanical ventilation, and mortality. It is highly recommended to actively promote the vaccination among this population.
在疫情期间，建议癌症患者优先接种新冠疫苗；然而，这些患者未被纳入评估现有疫苗的初始研究中。为了确定在哥伦比亚的一组癌症患者中，接种新冠疫苗对预防与感染相关并发症风险的影响。开展了一项基于国家癌症患者和新冠病毒19感染登记处ACHOC-C19的分析性观察队列研究。数据收集时间为2021年6月至2021年10月。纳入标准为：年龄大于18岁、确诊患有癌症且确诊感染新冠病毒19的患者。对未接种疫苗组和接种疫苗组的数据进行了比较。评估的结果包括新冠病毒19诊断后30天内的全因死亡率、住院情况以及机械通气需求。通过相对风险（RR）、绝对风险降低率（ARR）和治疗所需人数（NNT）对效果进行估计。使用广义线性模型进行多变量分析。：共纳入896例患者，其中470例年龄大于60岁（52.4%），59%为女性（n = 530）。接种疫苗组招募了172例患者，未接种疫苗组招募了724例患者（比例为1比4.2）。未接种疫苗患者与接种疫苗患者临床结局的累积发生率分别为：住院率42%（95%置信区间：38.7%-46.1%）对29%（95%置信区间：22.4%-36.5%）；有创机械通气需求率8.4%（n = 61）对4.6%（n = 8）；全因死亡率17%（n = 123）对4.65%（n = 8）。在我们的研究人群中，未接种疫苗的癌症患者感染新冠病毒19后出现并发症（如住院、机械通气和死亡）的风险增加。强烈建议在这一人群中积极推广疫苗接种。
